CELZ
Price
$1.91
Change
-$0.06 (-3.05%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
4.99M
EDIT
Price
$1.61
Change
+$0.05 (+3.21%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
134.77M
5 days until earnings call
Ad is loading...

CELZ vs EDIT

Header iconCELZ vs EDIT Comparison
Open Charts CELZ vs EDITBanner chart's image
Creative Medical Technology Holdings
Price$1.91
Change-$0.06 (-3.05%)
Volume$200
Capitalization4.99M
Editas Medicine
Price$1.61
Change+$0.05 (+3.21%)
Volume$31.49K
Capitalization134.77M
CELZ vs EDIT Comparison Chart
Loading...
CELZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELZ vs. EDIT commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and EDIT is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CELZ: $2.00 vs. EDIT: $1.56)
Brand notoriety: CELZ and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELZ: 32% vs. EDIT: 49%
Market capitalization -- CELZ: $5.22M vs. EDIT: $134.77M
CELZ [@Biotechnology] is valued at $5.22M. EDIT’s [@Biotechnology] market capitalization is $134.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELZ’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • CELZ’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than CELZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELZ’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 5 bullish TA indicator(s).

  • CELZ’s TA Score: 5 bullish, 3 bearish.
  • EDIT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CELZ is a better buy in the short-term than EDIT.

Price Growth

CELZ (@Biotechnology) experienced а +1.01% price change this week, while EDIT (@Biotechnology) price change was +22.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

CELZ is expected to report earnings on Aug 30, 2023.

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($135M) has a higher market cap than CELZ($4.99M). EDIT YTD gains are higher at: 22.835 vs. CELZ (-13.420). CELZ has higher annual earnings (EBITDA): -5.52M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. CELZ (6.26M). CELZ has less debt than EDIT: CELZ (2.74M) vs EDIT (35M). EDIT has higher revenues than CELZ: EDIT (32.3M) vs CELZ (11K).
CELZEDITCELZ / EDIT
Capitalization4.99M135M4%
EBITDA-5.52M-233.11M2%
Gain YTD-13.42022.835-59%
P/E RatioN/AN/A-
Revenue11K32.3M0%
Total Cash6.26M270M2%
Total Debt2.74M35M8%
FUNDAMENTALS RATINGS
CELZ vs EDIT: Fundamental Ratings
CELZ
EDIT
OUTLOOK RATING
1..100
7518
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
9158
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (22) in the Biotechnology industry is somewhat better than the same rating for CELZ (65) in the null industry. This means that EDIT’s stock grew somewhat faster than CELZ’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CELZ (100) in the null industry. This means that EDIT’s stock grew similarly to CELZ’s over the last 12 months.

EDIT's SMR Rating (95) in the Biotechnology industry is in the same range as CELZ (95) in the null industry. This means that EDIT’s stock grew similarly to CELZ’s over the last 12 months.

EDIT's Price Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for CELZ (91) in the null industry. This means that EDIT’s stock grew somewhat faster than CELZ’s over the last 12 months.

CELZ's P/E Growth Rating (52) in the null industry is somewhat better than the same rating for EDIT (100) in the Biotechnology industry. This means that CELZ’s stock grew somewhat faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELZEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 21 days ago
85%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 17 days ago
89%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CELZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AABFX13.440.09
+0.67%
Thrivent Dynamic Allocation A
ODICX36.44N/A
N/A
Invesco Discovery C
NSOPX15.35N/A
N/A
North Star Opportunity A
GGHSX36.76N/A
N/A
Invesco Health Care R6
QDISX15.70N/A
N/A
Fisher IIG Stock for Ret Plns

CELZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELZ has been loosely correlated with LABFF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CELZ jumps, then LABFF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELZ
1D Price
Change %
CELZ100%
-0.99%
LABFF - CELZ
35%
Loosely correlated
N/A
EDIT - CELZ
31%
Poorly correlated
N/A
WVE - CELZ
30%
Poorly correlated
+3.51%
GNPX - CELZ
28%
Poorly correlated
+3.01%
RXRX - CELZ
25%
Poorly correlated
-0.89%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
N/A
CRSP - EDIT
53%
Loosely correlated
-1.76%
AXON - EDIT
52%
Loosely correlated
+3.82%
PRME - EDIT
51%
Loosely correlated
+4.14%
VCYT - EDIT
49%
Loosely correlated
+1.08%
NTLA - EDIT
49%
Loosely correlated
-2.65%
More